Sarepta Therapeutics, Inc. SRPT
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD. We are also developing potential therapeutic candidates through our partnered program with Arrowhead for the treatment of Facioscapulohumeral muscular dystrophy ("FSHD"), myotonic dystrophy type 1 ("DM1"), Spinocerebellar ataxia ("SCA"), Idiopathic Pulmonary Fibrosis ("IPF"), Huntington's disease and other neuromuscular and skeletal diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.86B | $1.79B | $1.14B | $843.8M | $612.4M | $455.9M | $380.8M | $301.0M | $154.6M | $5.4M |
| Cost of revenue | $25.5M | — | — | — | — | — | — | — | — | $130.0K |
| Gross profit | $1.84B | — | — | — | — | — | — | — | — | $5.3M |
| R&D | — | — | — | — | — | — | — | $401.8M | $166.7M | $188.3M |
| SG&A | $491.7M | $557.9M | $481.9M | $451.4M | $282.7M | $317.9M | $284.8M | $207.8M | $122.7M | $83.7M |
| Total operating expenses | $2.90B | $1.68B | $1.51B | $1.47B | $1.16B | $1.10B | $1.09B | $644.7M | $326.2M | $272.2M |
| Operating income | -$699.8M | $218.1M | -$267.8M | -$536.2M | -$459.7M | -$564.2M | -$705.6M | -$343.6M | -$171.6M | -$266.7M |
| Interest expense | $38.1M | $18.4M | $22.0M | $53.2M | $63.5M | $59.9M | $30.7M | $33.7M | $5.8M | $1.9M |
| Pre-tax income | -$702.2M | $260.8M | -$520.1M | -$690.0M | -$418.9M | -$553.1M | -$713.9M | -$362.6M | -$48.6M | -$267.3M |
| Income tax | $11.2M | $25.5M | $15.9M | $13.5M | $168.0K | $1.1M | $1.2M | $692.0K | $2.1M | — |
| Net income | -$713.4M | $235.2M | -$536.0M | -$703.5M | -$418.8M | -$554.1M | -$715.1M | -$361.9M | -$50.7M | -$267.3M |
| EPS, basic | -7.13 | 2.47 | -5.80 | -8.03 | -5.15 | -7.11 | — | — | — | — |
| EPS, diluted | -7.13 | 2.34 | -5.80 | -8.03 | -5.15 | -7.11 | -9.71 | -5.46 | -0.86 | -5.49 |
| Shares, diluted (wtd. avg.) | 100.1M | 107.9M | 92.4M | 87.6M | 81.3M | 78.0M | 73.6M | 66.2M | 58.8M | 48.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $801.3M | $1.10B | $428.4M | $966.8M | $2.12B | $1.50B | $835.1M | $370.8M | $599.7M | $122.4M |
| Short-term investments | $138.4M | $251.8M | $1.25B | $1.02B | $0 | $435.9M | $289.7M | $803.1M | $479.4M | $195.4M |
| Receivables | $398.2M | $602.0M | $400.3M | $214.6M | $153.0M | $101.3M | $90.9M | $49.0M | $29.5M | $5.2M |
| Inventory | $914.7M | $750.0M | $322.9M | $204.0M | $186.2M | $232.0M | $171.4M | $125.4M | $83.6M | $12.8M |
| Total current assets | $2.54B | $3.07B | $2.58B | $2.56B | $2.60B | $2.49B | $1.47B | $1.43B | $1.23B | $373.5M |
| Property, plant and equipment | $345.1M | $340.3M | $227.2M | $180.0M | $191.2M | $190.4M | $129.6M | $97.0M | $43.2M | $37.8M |
| Other intangibles | $28.9M | $26.9M | $29.6M | $7.6M | $14.2M | $13.6M | $12.5M | $11.6M | $14.4M | $8.1M |
| Total assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424.1M |
| Accounts payable | $280.8M | $214.4M | $164.9M | $95.9M | $76.7M | $111.1M | $68.1M | $33.8M | $8.5M | $29.7M |
| Short-term debt | — | $0 | $105.5M | $0 | — | — | — | — | — | — |
| Total current liabilities | $1.10B | $731.7M | $653.7M | $619.6M | $452.7M | $416.0M | $264.8M | $173.7M | $88.3M | $75.4M |
| Long-term debt | $140.5M | $1.14B | $1.24B | $1.54B | $563.7M | — | — | $420.6M | $431.1M | $17.7M |
| Total liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $609.8M | $518.7M | $87.4M |
| Retained earnings | -$4.88B | -$4.21B | -$4.45B | -$3.91B | -$3.21B | -$2.85B | -$2.29B | -$1.58B | -$1.22B | -$1.17B |
| Total equity | $1.14B | $1.53B | $859.3M | $384.9M | $928.0M | $761.8M | $818.2M | $1.03B | $789.2M | $336.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$205.5M | -$205.8M | -$501.0M | -$325.3M | -$443.2M | $107.5M | -$456.5M | -$388.7M | -$232.0M | -$245.8M |
| Depreciation and amortisation | $44.5M | $37.7M | $44.4M | $41.9M | $38.0M | $26.9M | $24.5M | $12.2M | $8.1M | $5.6M |
| Stock-based compensation | $123.4M | $184.3M | $182.5M | $233.0M | $113.9M | $108.1M | $78.6M | $50.1M | $30.5M | $30.0M |
| Capital expenditure | $102.0M | $137.0M | $76.1M | $30.8M | $38.5M | $82.2M | $59.6M | $61.2M | $12.0M | $5.3M |
| Investing cash flow | $69.6M | $755.6M | -$165.8M | -$1.05B | $495.4M | -$121.7M | $286.7M | -$370.5M | -$178.8M | -$90.2M |
| Financing cash flow | -$168.3M | $124.8M | $125.0M | $232.5M | $561.6M | $682.3M | $642.6M | $530.1M | $888.1M | $378.1M |
| Buybacks | $25.0M | $0 | $0 | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-177247.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $154.6M | $301.0M | $380.8M | $455.9M | $612.4M | $843.8M | $1.14B | $1.79B | $1.86B |
| Gross profit | $5.3M | — | — | — | — | — | — | — | — | $1.84B |
| Net income | -$267.3M | -$50.7M | -$361.9M | -$715.1M | -$554.1M | -$418.8M | -$703.5M | -$536.0M | $235.2M | -$713.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |